The 6th Annual
Midwest Neglected Infectious Diseases Meeting
August 27-28th 2017
University of Notre Dame College of Science
Center for Rare and Neglected Diseases
Registration is Free but required.
To register please contact Corianne Kellems email@example.com
After a hiatus in 2016, MNID is back! The MNID meeting is the only regional meeting in the Midwest that features forefront research focused on the pathogenesis of fungal and parasitic diseases. This meeting fills an important void, as the parasitic and fungal diseases, while crucially important; do not receive sufficient “press” at many major biology meetings. Over the past years the meetings have included 100-130 scientists from seven states; Wisconsin, Illinois, Indiana, Michigan, Ohio, Iowa, and Missouri.
For the 2017 meeting, we are also planning a joint session on with the 2107 Midwest Microbial Pathogenesis Meeting, on August 27th.
Preliminary Program of speakers listed below.
Short (10 min) talks and Abstract submission. Short talks will be selected from submitted abstracts. Deadline August 5th 2017. Please submit abstracts (maximum length 200 words) by email to Corianne Kellems firstname.lastname@example.org
Poster deadline. August 23, 2017
Dr. Laura Knoll, University of Wisconsin, Madison Wisconsin
Toxoplasma and co-infections.
Dr. Min Zhang, Indiana University School of Medicine (Sullivan Lab)
Malaria: latency and translational control.
Dr. Vern Carruthers, University of Michigan
Microbial invasion egress and survival
Dr. Chad Rappeley, Ohio State University
Fungal pathogenes: Histoplasma capsulatum
Dr. Vicki Jeffers, Indiana University School of Medicine (Sullivan Lab)
Toxoplasma: epigenetics and drug resistance.
Dr. Michal Olszewski, University of Michigan
Immunology of Cryptococcus
Dr. Ke Hu, Indiana University, Bloomington
Toxoplasma cell biology
Dr. Steven Templeton, Indiana University School of Medicine
Dr. Kasturi Haldar, University of Notre Dame
Drug Resistance Plasmodium: Artemisinins
Dr. Raj Gaji Indiana University School of Medicine (Arrizabalaga lab)
Toxoplasma lytic cycle, kinases.
Dr. Miguel Morales, University of Notre Dame
Development of novel anti-Leishmania chemotherapeutics.